Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024 lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.
NEW YORK, Feb. 1, 2024 /PRNewswire/ Immunic, Inc. , a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and.
team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference.
Treating multiple sclerosis (MS) in its earlier stages with Ocrevus (ocrelizumab) can substantially lower disease activity and lessen damage to the nervous system, new research demonstrates.
“We are encouraged by these new analyses showing that early treatment with Ocrevus may significantly control disease progression in both relapsing-remitting MS and in primary progressive MS,” Levi Garraway, MD, PhD, chief medical officer and head of global product development at Genentech (a member of the Roche Group), which makes Ocrevus, said in a press release.
Press release content from Business Wire. The AP news staff was not involved in its creation.
New Genentech Data at 2021 AAN Highlight Impact and Breadth of Expanding Neuroscience Portfolio
April 8, 2021 GMT
SOUTH SAN FRANCISCO, Calif. (BUSINESS WIRE) Apr 8, 2021
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new data for its approved and investigational medicines for the treatment of neurological disorders will be presented at the 73rd American Academy of Neurology (AAN) Annual Meeting being held virtually April 17-22, 2021. These new data include 23 abstracts highlighting the expanding Genentech neuroscience portfolio across six therapeutic areas, including Evrysdi™ (risdiplam) for spinal muscular atrophy (SMA), Ocrevus ® (ocrelizumab) in relapsing and primary progressive multiple sclerosis (RMS and PPMS), investigational Bruton’s tyrosine kinase inhibitor (BTKi) fenebrutinib in Phase III trials for RMS and PPMS, Enspryng™ (sat
(0)
EVRYSDI 2-year FIREFISH Part 2 data show improvement in motor function in infants with Type 1 spinal muscular atrophy (SMA)
OCREVUS data show its consistent benefit on slowing disease progression in relapsing multiple sclerosis (RMS) and primary progressive MS (PPMS)
Data for ENSPRYNG in neuromyelitis optica spectrum disorder (NMOSD) reinforce safety and efficacy, including in patients with concomitant autoimmune diseases (CAIDs)
Data for investigational MS medicine fenebrutinib support its safety profile and high potency
Additional presentations on investigational programmes, including Alzheimer s disease and Huntington s disease, help advance scientific understanding of neurological disorders
Basel, 8 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data for its approved and investigational medicines for the treatment of neurological disorders will be presented at the 73rd American Academy of Neurology (AAN) Annual Meeting being held virtually Apr